Arylsulfonamido-substituted hydroxamic acids

A compound of formula I, wherein Ar is phenyl which is mono-substituted by C1-C7-alkoxy; R is lower alkyl; phenyl or pyridyl; R1 is C8-C10-cycloalkyl; pyrrolidinyl; N-lower alkoxycarbonyl-(piperidyl or pyrrolidinyl); C5-C10-oxacycloalkyl; hydroxy-C5-C10-cycloalkyl; hydroxy-C5-C10-oxacycloalkyl; N-di-lower alkylamino-C5-C10-cycloalkyl; 2-oxo-(hexahydroazepinyl); N-di-lower alkylamino-lower alkanoyl-piperidyl, N-di-lower alkylamino lower alkanoylamino-C5-C10 cycloalkyl; di-lower alkoxy-lower alkyl; or lower alkoxy carbonylamino-C5-C10 cycloalkyl; R2 is hydrogen; a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof. Said compounds have valuable pharmaceutical properties and are effective especially as matrix metalloproteinase inhibitors, for example for the treatment of arthritis. The are prepared in a manner known per se.